We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV

By LabMedica International staff writers
Posted on 30 Jun 2026

Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. More...

In England, about one in 20 people living with HIV are unaware of their status, underscoring persistent gaps in routine screening pathways. New findings now demonstrate how a large-scale emergency department opt-out testing initiative is detecting infections earlier and linking patients to care.

The UK National Health Service (NHS) Blood Borne Virus Opt-Out Testing Program is a first-of-its-kind large-scale initiative operating in hospital emergency departments (EDs). Adults attending EDs in 88 towns and cities with high HIV prevalence who are already having blood drawn are routinely tested for HIV, hepatitis B, and hepatitis C unless they opt out. Individuals with positive results are then offered specialist support and a treatment plan.

According to the latest NHS data, the program has identified 1,900 previously undiagnosed HIV cases since it launched in April 2022. An economic evaluation published in The Lancet HIV and led by the University of Bristol and the National Institute for Health and Care Research (NIHR) estimated that 802 diagnoses from the program’s initial phase could avert about 187 HIV-related deaths and 28 new infections over 20 years.

Research by the UK Health Security Agency (UKHSA) found that 93% of newly diagnosed individuals reached by the initiative had no record of a prior HIV test, indicating that the model is engaging people unlikely to be tested through other pathways.

The study concluded the approach offers good value for the NHS, citing a low per-test cost and the clinical benefits of earlier diagnosis and treatment initiation. The program forms part of national efforts to reduce HIV transmission, with NHS leaders continuing the rollout and three additional hospitals expected to begin ED testing by April 2027. The government’s HIV Action Plan 2025–2030 also sets out continued investment to sustain opt-out testing for HIV, hepatitis B, and hepatitis C in high-prevalence areas.

“At around £6 per HIV test, the program is good value for money for the NHS, and importantly has led to linkage to treatment to improve the health and lifespan of many people who were previously living with undiagnosed HIV,” said Dr. Josephine Walker, lead author at the University of Bristol and NIHR Health Protection Research Unit in Evaluation and Behavioural Science.

“Knowing your HIV status is as important as checking your blood pressure, and our pioneering NHS Blood Borne Virus Opt-Out Testing Program is helping hundreds of people get a diagnosis—often before they have any symptoms at all—which means they have access to life-saving treatment," said Professor Francesca Swords, national medical director for the NHS.

"NHS staff are committed to improving early detection of HIV and other blood-borne viruses, and improving awareness of these health conditions to reduce the chance of people unknowingly passing it on to others. The successful rollout of this initiative in hospital EDs is an excellent example of how the NHS is working to make every contact with patients matter by supporting people to stay well, access treatment, save lives and make the best use of its resources,” added Prof. Swords.

Related Links
University of Bristol 
NIHR


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Urine Analyzer
respons® UDS100
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.